Uncommon opportunistic fungi: new nosocomial threats  by Groll, A.H. & Walsh, T.J.
Uncommon opportunistic fungi: new nosocomial threats 
A. H. Groll and T. J.  Walsh 
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA 
During the past two decades opportunistic hngal infections have emerged as important causes of morbidity 
and mortality in patients with severe underlying illnesses and compromised host defenses. While Aspergillus and 
Candida spp. collectively account for the majority of these infections, recent epidemiological trends indicate a 
shift towards infections by Aspergillus spp., nonalbicans Candida spp., as well as previously uncommon 
opportunistic fungi. Apart &om an expanding number of different Zygomycetes, previously uncommon 
hyaline lilamentous fungi (such as Fusarium species, Acremonium species, Paecilomyres species, Pseudallescheria 
boydii, and Scedosporium prol$cans), dematiaceous filamentous fungi (such as Bipolaris species, Cladophialophora 
bantiana, Dactylaria gallopava, Exophiala species, and Alternaria species) and yeast-like pathogens (such as 
Trichosporon species, Blastoschizomyces capitatus, Malassezia species, Rhodotomla rubra and others) are increasingly 
encountered as causing life threatening invasive infections that are often refractory to conventional therapies. 
On the basis of past and current trends, the spectrum of fungal pathogens will continue to evolve in the settings 
of an expanding population of immunocompromised hosts, selective antifungal pressures, and shifting 
conditions in hospitals and the environment. An expanded and refined drug arsenal, further elucidation of 
pathogenesis and resistance mechanisms, establishment of in vitro/in vivo correlations, incorporation of 
pharmacodynamics, combination- and immunotherapies offer hope for substantial progress in prevention 
and treatment. 
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INTRODUCTION 
Opportunistic fungal infections have emerged as important 
causes of morbidq and mortality in patients with severe 
underlymg illnesses and compromised host defenses [ 11. 
Whereas AspergiilIus spp. and Candida spp. collectively account 
for the majority of deeply invasive and life-threatening fungal 
infections, epidemiological trends during the past decade 
indicate a shf t  towards infections by Aspergillus spp., nonalbicans 
Candida spp., as well as previously uncommon opportunistic 
fung [2-71. The latter include, among others, yeasts such as 
Tnchosporon beigelii, filamentous fun@ such as Fusarium spp., a 
large variety of dematiaceous moulds, the Zygomycetes as well 
as endemic dimorphic fungi such as Penicillium mamefei [8-111 
Conceptually, these emerging fungal infections develop in a 
dynamic interplay of altered hosts, permissive environmental 
conditions, and selective antifungal pressures (Figure 1). 
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OVERVIEW 
The emerging fungal pathogens may be clashed as filamentous 
fun@ (moulds) and yeasts; they may be further classified as hyaline 
or dematiaceous (pigmented). Filamentous fungi also are classified 
as opportunistic or endemic (dimorphic), and as septated and 
nonseptated (belonging to the class of Zygomycetes) (Figure 2). 
Similar to the classic fungal opportunists, the patient population at 
risk is broad. In general, deficiencies in the number or function 
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Figure 1 Concepts in emerging fungal infections. 
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Figure 2 Practical working schema of common and uncommon fungi encountered in immunocompromised patients. 
of phagocytic cells are associated with the large variety of 
opportunistic yeasts and moulds, while deficiencies or 
imbalance of T-lymphocyte fimction are M e d  to the dimorphic 
moulds as well as to opportunistic moulds in the setting of chronic 
@-vs.-host disease and advanced HIV-mfection [12]. Important 
additional nonimmunologcal factors mclude the necessary 
exposure to the organism, pre-existing tissue damage, and, largely 
limited to yeast-hke organisnls, the presence of indwehg vascular 
catheters, colonization of mucocutaneous sutfaces, and use of 
broad-spectrum antibiotics and/or parented nutrition [13]. 
As airborne pathogens, the emerging opportunistic moulds 
that cause basic disease patterns may be virtually indistinguish- 
able &om those of Aspegillus spp. Apart from primary invasive 
infections of the skin and subcutaneous tissues, they affect 
primarily the sinobronchial tree and have a propensity for 
dissemination, in particular into the central nervous system. 
Importantly, some of the hyaline moulds, including Fusarium 
spp., Paecilomyces spp., and Acremonium spp., express small 
adventitious structures in tissues that facilitate dissemination and 
detection of the organism in blood culture systems. Yeast-like 
pathogens mostly follow the pattern of fungemia and 
disseminated infection known from Candida spp., while 
infections caused by Penicillium marngei resemble those of 
disseminated histoplasmosis or cryptococcosis. 
Invasive infections by the emerging fungal opportunists are 
associated with high case fatality rates that appear to even surpass 
those known from the classic opportunists. Because ofthe lack of 
specific clinical, radiographic and histologd features and the 
absence of diagnostic surrogate markers in blood, the diagnosis 
depends on the identiiication of the organism by means of culture 
based methods. The therapy of most emerging pathogens is not 
standardized but relies on the use of high-dose amphotericin B 
(AmB), appropriate surgical measures, and reversal ofthe underlying 
impairment of host defenses (see Tables 6 and 7 later in this .dele). 
However, some of these organisms are not inherently susceptible to 
AmB and may require therapies with alternative agents. 
This article reviews key emerging opportunistic bngal 
pathogens that present a risk to immunocompromised patients. 
Since separate articles in t h i s  supplement are devoted to 
Candida spp. and Aspergillus spp., the emergence of non- 
albicans Candida spp., azole-resistant Candida albirans and 
unusual Aspergillus spp. will not be discussed. Cryptorocrus 
neoformans and the endemic moulds of the Americas have been 
comprehensively reviewed elsewhere [14-251 and are likewise 
not the subject of this article. 
EMERGING FILAMENTOUS FUNGI 
Hyaline septated moulds 
Fusarium species 
Fusarium spp., once considered to cause only infections of the 
skin, nail, and cornea, are representative of the emerging 
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group of hyaline moulds which cause sinopulmonary and 
disseminated infection particularly in granulocytopenic pa- 
tients undergoing intensive antileukemic chemotherapy or 
allogeneic hematopoetic stem cell transplantation [26-301. 
Indeed, in some cancer centers, Fusarium spp. have emerged as 
the second most common filamentous fungal pathogen after 
Aspergillus [31]. Characterized by canoe-shaped macroconidia, 
Fusarium solani, Fusarium oxysporum, and Fusarium monilqome 
(Fusarium verticilloides) are the most common species of this 
ubiquitous mould and plant pathogen 1321. 
The primary portals of entry of Fusarium spp. include lungs, 
paranasal sinuses, vascular catheters, and breaches in the 
integrity of the skin, including the periungual regons of the 
toes. Defenses of the human host depend on pulmonary 
alveolar macrophages for conidia and neutrophils for hyphal 
elements. Among immunocompromised hosts, neutropenia 
appears to be the critical factor, with corticosteroids further 
adding to the immune-impaired state predisposing to invasive 
fusariosis. Similarly to Aspergillus, this organism is highly 
angioinvasive and leads to hemorrhagc infarction in pancy- 
topenic hosts [27,28]. Fusarium spp. can elaborate potentially 
lethal mycotoxins in crops; at present, it is unclear whether 
mycotoxins can be formed within human tissue and contribute 
to disease [10,32]. 
The usual initial presentation of invasive fusariosis is 
persistent fever in a profoundly neutropenic patient. Apart 
from sinusitis, established infections are characterized by 
pulmonary infiltrates, metastatic s h n  lesions and dissemination 
to multiple tissue sites [27,28]. Perhaps as a result of the 
occurrence of adventitious sporulation in tissues as mechanism 
for dissemination [33], Fusarium spp. can be recovered in 
routine blood cultures in 4040% of cases [28,29]. Histo- 
pathological examination of infected tissues, however, is often 
nonspecific, and on the basis of septate hyaline branching 
hyphae it is difficult to hstinguish Aspergillus from other 
hyaline moulds [34]. Thus, definite diagnosis still relies on the 
cultural recovery of the organism from infected tissues or the 
bloodstream. In the near future, however, PCR techniques 
may detect Fusarium spp. earlier in blood cultures or 
bronchoalveolar lavage samples and simultaneously distinguish 
it from other filamentous fun@ [35]. 
Responses to treatment of disseminated fusariosis are 
hampered by marginally effective chemotherapy, particularly 
in patients with persistent deficiencies in host defenses [27,29]. 
Overall mortality rates range from 52 to 70%, and are close to 
100% in patients who do not recover from neutropenia [26- 
301. Fusariosis may be resistant to amphotericin B [36,37] and 
breakthrough infection during empirical therapy with am- 
photericin B may occur. One can sometimes achieve 
stabilization of infection, albeit transiently, with higher doses 
of amphotericin B in the range of 1.0-1.5 mg/kg or with lipid 
formulations of  amphotericin B using a dose of at least 5 mg/ 
kg per day [38]. 
In neutropenic patients, rapid recovery &om neutropenia is 
essential for survival. However, while recovery from neutro- 
penia is an essential condition, it may not be a sufficient 
condition, as the infection may s d  continue to progress. In 
other cases, chronic disseminated infection may ensue with 
consequences similar to those of chronic disseminated candi- 
diasis [26]. Newer therapeutic strategies, however, provide 
some opportunities for hope: (1) granulocyte or granulocyte/ 
macrophage colony stimulating factors in patients not yet 
receiving them (2) granulocyte transfusions from GCSF- 
stimulated donors, and (3) new antifungal agents. While 
fluconazole and itraconazole are not active against Fusarium 
spp., limited in vitro and experimental in vivo data and some 
anecdotal reports suggest that new antifungal triazoles such as 
posaconazole and voriconazole may exert activity agamst some 
Fusarium spp. [3943]. However, in the absence of fungicidal 
activity of these agents in viho [44-46] and lackmg clinical data 
for treatment in persistently neutropenic hosts, therapy with 
conventional amphotericin B [47] or one of the lipid 
formulations of amphotericin B [38] remain the standard initial 
approach to these devastating infections (Table 1). 
Acremonium species 
Acremonium species are environmentally widespread hyaline 
moulds that, when grown in culture, produce small conidia on 
slender phiahdes that resemble an early growth of Fusarium 
species. Further incubation, however, does not reveal the 
characteristic macroconidia observed in Fusarium species. 
Similar to Fusarium and Paecilomyces spp., Ammonium spp. 
may produce s m a l l  adventitious unicellular forms (phialoco- 
nidia) during infection, which may facilitate dissemination and 
recovery from the bloodstream [48]. 
Anemonium causes a spectrum of infections, rangmg from 
mycotic keratitis and mycetoma in normal hosts to fungemia 
and hsseminated infection in immunocompromised patients 
[48-511. The lungs and gastrointestinal tract are the apparent 
portals of entry in immunocompromised patients. Cutaneous 
lesions may develop during fungemia and disseminated 
infection. As is true for most emerging pathogens, the optimal 
therapeutic approach to Acremonium infections remains to be 
determined. In general, Acremonium spp. display little ruscept- 
ibility to current antifungal agents, with best activity seen for 
amphotericin B [49,51]. However, reported MIC values are 
comparatively high and clinical responses to amphotericin B 
therapy in immunocompromised hosts are variable, suggesting 
that Acremonium species may be resistant to conventional 
dosages of amphotericin B. Acremoniurn infections that are 
unresponsive to conventional amphotericin B therapy are 
candidates for treatment with one of the lipid formulations of 
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Table 1 Chemotherapy of invasive infections by hyaline septated moulds 
Fungal disease Management  
Fusarium infections D-AmB[1.0-1.5 mg/kg/d] or 
F. solani 
F. oxysporon 
F. moniliforme Second line: 
ArnB lipid formulations[5 mg/kg/d starting dose] 
Acremonium infections Third-generation antifungal triazoles 
[investigational]T 
Paecilomyces infections 
P. variotii 
P. lilacinus 
Pseudallescheria infections 
Pseudallescheria boydii 
Scedosporium apiospermum 
Scedosporium prolificans 
Trichoderma infections 
T. longibrachiatum 
Scopulariopsis infections 
Scopulariopsis brevicaulis 
D-Am6 [l .0-1.5 mg/kg/d] or 
ArnB lipid formulations[5 mg/kg/d starting dose] 
[first choice for I? lilacinus] 
Second line: 
Itraconazole51 [200-600 mg/d] [P. varioti only] 
Third-generation antifungal triazoles 7 [investigational] 
D-AmB [l .O-1.5 mg/kg/d] or 
AmB lipid formulations [5 mg/kg/d starting dose] 
Second line: 
Itraconazolep$ [200-600 mg/d] 
Third-generation antifungal triazoles 7 [investigational] 
No therapy with documented efficacy; consider infections 
high-dose lipid based 
AmB [ 2 5  mg/kg/d] or combination of itraconazole and terbinafine 
D-AmB[1.&1.5 mg/kg/d] or 
AmB lipid formulations[5 mg/kg/d starting dose] 
Second line: 
Third-generation antifungal triazolesi [investigational] 
Deep dermatophytic infections Fluconazole 400 mg/d or 
ltraconazole 200-400 mg/d or Trichophyton spp. 
Microsporon spp. Terbinafine 250 mg/d 
Epidermophyton spp. 
qlncludes posaconazole, ravuconazole, and voriconazole. 
$Monitoring of serum levels recommended (>  0.5 Fg/mL [HPLC] or > 2.0 pg/mL [bio-assay] before next dose). Loading dose: 200 mg t id over 3 
days. Maximum: 600 rng/d. Intravenous therapy: 200 mg bid over 2 days, followed by 200 mg qd (maximum: 1 4  days). 
$May also be indicated as first line therapy in stable patients with non life-threatening infections. 
amphotericin B or, perhaps, one of the investigational 
antifungal triazoles [39] (Table 1). 
Paecilomyces species 
Paecilomyces spp. are common environmental hyaline moulds 
associated with keratitis and soft tissue infections in immuno- 
competent hosts, but may become the cause of deep infection 
in immunocompromised patients. The apparent portals of 
entry for this organism are the respiratory tract, indwelling 
catheters and the skin [52,53]. The case of the skin as portal of 
entry is illustrated by an outbreak of disseminated infection 
due to Paecilomyces lilacinus, which occurred on a bone marrow 
transplantation unit. A medicated skin cream repeatedly 
obtained from the same jar was the common source and 
vehicle for transmission of the P. lilacinus [54]. Invasive 
Paecilomyces infections may manifest as fungemia, soft tissue 
infections, pneumonitis and disseminated infection [52-581. 
As already noted for Fusarium and Ammonium, Paecilomyces can 
form adventitious structures within infected tissues that are 
morphologically consistent with microconidla and can 
disseminate widely through the bloodstream [33]. 
While management of locahzed infections includes surgical 
resection of infected foci where feasible, the optimal agent for 
chemotherapy of invasive infections has not been identified. A 
recent investigation of 52 isolates of 10 Paecilomyces species 
showed high MIC90 for all agents tested. Evaluation of 
MIC50s indicated overall good activity of amphotericin B and 
itraconazole, while fluconazole and flucytosine had poor 
efficacy. However, there were significant susceptibility 
differences among the different species, and all antifbngal 
agents assayed showed low efficacy against P. lilacinus [59]. 
Promising in vitro data have been presented for the new 
triazoles [39,60]. Nevertheless, correlation to clinical out- 
comes has not been established for Paecilomyces spp.. and 
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therapy must be adjusted to clinical response. In a conservative 
approach, high-dose amphotericin B is the initial therapeutic 
intervention for invasive infections in the immunocompro- 
mised host; the lipid formulations of amphotericin B are 
reserved for patients refiactory to or intolerant of D-AmB. 
The role of itraconazole and the investigational triazoles in the 
primary treatment of invasive infections is unclear, in 
particular in the setting of persistent neutropenia (Table 1). 
Pseudallescheria boydii 
Pseudallescheriu boydii is a hyaline mould that is characterized 
microbiologcally by terminal annelloconidia and typical 
cleistothecia in the sexual state (teleomorph form). Some 
isolates do not &splay a sexual state (synanamorph form) even 
under appropriate growth conditions. For such isolates, the 
designation Scedosporium upiospermum is used. It is unknown 
whether these different growth characteristics in vitro are 
associated with different pathogenic behavior in vivo. P. boydii 
may cause pneumonias, sinusitis, CNS infection, endocarditis, 
disseminated disease, and mycetomas, attendant with severe 
morbidity and mortality [61-681. In a review of 31 reported 
cases ofinvasive infections, 61% died despite antifungal therapy; 
among eight patients with locahzed musculoskeletal soft tissue 
infection, seven required surgery, and three amputation [61]. In 
immunosuppressed patients, the principal portal of entry is the 
respiratory tract. Widespread dissemination from the lungs may 
ensue to other target organs. Cutaneous nodules may be a 
harbinger for multifocal dissemination to other organs including 
the central nervous system. Diagnostic procedures and 
approaches are similar to those for invasive aspergdosis. 
Essential to the treatment of infections due to P. boydii and 
its synanamorph is the correct microbiological diagnosis 
established by culture [67,69]. Infections caused by these 
pathogens are often refractory to conventional antifungal 
therapy, either because of persistently impaired host responses 
or because of intrinsic microbiological resistance to antifungal 
compounds [61]. The antifungal activity of amphotericin B in 
vitro is strain dependent and not consistently cidal [70]. 
Similarly, while itraconazole and particularly voriconazole 
have very useful inhibitory activity [41,44,46,70-721, this 
activity appears not to be fungicidal [46,70]. The echinocan- 
dins have been shown to have inhibitory in vitro activity 
against P. boydii [44,73,74], but antifungal efficacy in vivo has 
not been demonstrated. In the absence of systematic preclinical 
and clinical data, the optimal treatment for invasive pseudal- 
lescheriasis remains to be defined. In the persistently 
neutropenic patient, high-dose amphotericin B may still be 
the preferred initial approach with a low threshold for second- 
line therapy with itraconazole, voriconazole or one of the 
other still investigational novel broadspectrum triazoles. In less 
severely immunocompromised patient settings, the antifungal 
triazoles may represent a valid alternative to amphotericin B. 
Nevertheless, essential to survival from invasive pseudal- 
lescheriasis is the reversal of the underlying cause of 
immunosuppression and aggressive surgical interventions for 
amenable lesions. The role of recombinant cytokines and 
immunomodulation is controversial, but extrapolations fiom 
isolated case reports and work with other filamentous fungi 
may be applicable to this infection [75,76] (Table 1). 
Scedosporium prolificans 
An increasingly recognized pathogen morphologically related 
to P. boydii is Scedospotium prolijicuns (formerly Scedosporium 
inflatum). This organism has no known sexual state. A rare cause 
of asymptomatic colonization and localized infections following 
penetrating trauma in immunocompetent individuals, S. 
prolijicuns causes rapidly fatal disseminated infections in im- 
munocompromised patients, particularly in those with neu- 
tropenia as a result of anticancer treatment or hematopoetic 
stem cell transplantation [77-791. As exemplified in one series of 
17 cases from Australia, localized disease was managed 
successfdy in immunocompetent patients with local resection, 
while disseminated disease in immunosuppressed patients was 
almost universally lethal [77]. Clinical hallmarks of disseminated 
S. prolijcum infections are a high rate of antemortem detection 
of the organism in blood cultures, disseminated hematogenous 
skin lesions, and signs of CNS-involvement 1791. The 
respiratory tract appears to be the most ftequent portal of entry, 
but isolated cases indicate that S. prolijcuns may also enter the 
blood stream through indwelling central venous catheters [78]. 
The geographic distribution of disseminated S. prolijicuns 
infections suggests a predilection for Spain and Australia [79]; 
it is unclear, however, whether there is an ecological 
background for this apparently particular distribution. 
S .  prolijcuns is considered resistant to all current antifungal 
agents, including the novel antifungal triazoles and the 
echinocandms [44,71,73,78]. Early recognition and prompt 
surgical therapy, if possible, is very important. Interferon-y and 
GM-CSF can enhance neutrophil superoxide production in vitro 
and may prove usefid as immunomodulatory adjunct [80]. Very 
recently, in vitro interaction studies have demonstrated synergistic 
in vitro activity ofthe combination ofitraconazole and terbinafine 
against 85% of the 20 clinical isolates tested; the minimum 
inhibitory concentrations of the combination were within the 
range of achevable plasma levels [81]. Animal models have been 
developed [82] and should help to clan6 whether this or other 
approaches may lead to improved outcomes from t h s  thus far 
largely untreatable hngal infection (Table 1). 
Trichoderma species 
Previously considered a saprophytic organism with low 
pathogenicity, several centers have recently reported infections 
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caused principally by Trichoderma longibrachiatum [83-851. 
Although the genus Trichodema is composed of numerous 
species, recent molecular studies indicate that virtually all 
human infections are caused by a single taxonomic ‘section’ 
composed of T. longibrachiatum [86]. 
Trichoderma spp. have been reported to cause pulmonary, 
cerebral, soft tissue and disseminated infections in immuno- 
compromised patients, including those with bone marrow or 
solid organ transplantation [83-85,87,88]. In tissues, the 
organisms appear as hyaline moulds that are indistinguishable 
from other hyalohyphomycetes. Lack of response of infections 
caused by these organisms to antifiungal chemotherapy are 
consistent with elevated MICs of conventional antifungal 
agents, including amphotericin B and itraconazole [84,88] in 
the few strains tested. Recovery f?om immunosuppression 
appears to be pivotal to the response of this organism to 
antifungal chemotherapy. In a manner similar to that of other 
opportunistic moulds, hgh-dose amphotericin B is the initial 
therapeutic intervention for invasive infections; the lipid 
formulations of amphotericin B are reserved for patients 
refractory to or intolerant of D-AmB. The investigational 
triazoles [41,42] may be considered as alternatives to 
conventional antifungal therapy in patients not responding to 
these agents (Table 1). 
Scopulariopsis brevicaulis 
Scopulariopsis brevicaulis is a saprophytic hyaltne mould that is 
associated with onychomycosis and occasionally, localtzed 
invasive infections following traumatic or surgical injury [89]. 
In immunocompromised pabents, S. brevicaulis can cause 
deeply invasive and msseminated infections with very poor 
outcome [89-921. Treatment for disseminated S. brevicaulis 
infections is largely empirical. Based on very limited in vitro 
susceptibility data, approaches to therapy may include 
amphotericin B or the investigational triazole voriconazole. 
However, the activity of these agents appears variable [39,72] 
(Table 1). Terbinafine may be effective in conjunction with 
surgery for locally invasive infections of skin and perhaps, 
subcutaneous soft tissues [89,93]. 
Dermatophytes 
Infections caused by dermatophytes (particularly Microsporurn 
and Trichophyton spp.) in immunocompromised patients may 
cause locally invasive infection extending into the dermis and 
causing painful erythematous, nodular or ulcerative lesions, 
including clinical variations of Majochi’s granuloma [94-961. 
Because the differential diagnosis of these varied lesions 
includes disseminated candidusis, disseminated aspergillosis, 
fusariosis and ecthyma gangrenosum, biopsy and culture are 
warranted 1961. Systemic itraconazole, fluconazole or terbina- 
fine are the preferred agents for severe dermatophytosis in 
immunocompromised patients [97] (Table 1). Terbinafine 
does not interact with compounds such as cyclosporins that are 
metabolized through the CYP3A4 pathway [93]. This relative 
low potential for drug-drug interactions may be useful, 
particularly in the management of transplant recipients. 
Dermatophytes may be ready  transmitted throughout a 
hospital unit [98-1001. Hence, appropriate infection control 
measures, including hand washing and the use of gloves and 
gowns, where appropriate, is important in preventing or 
containing a potential outbreak of nosocomial dermatophytosis. 
Dematiaceous septated moulds 
The dematiaceous septated moulds represent a diverse group 
of fungal pathogens, which have in common the presence of 
melanin-like pigments within the cell wall of their hyphae 
[101-1041. Among the most prevalent causes of human 
infection are Bipolaris spp., Cladophialophora bantiana (formerly, 
Xylohypha bantiana; Cladosporium bantianum, and Cladosporium 
trichoides), Dactylaria gallopava, Altemaria spp., Exophiala spp., 
Phialophora spp., and Cuwularia spp. While the dematiaceous 
moulds typically cause diseases in normal host, such as 
locahzed lesions of skin and subcutaneous tissues following a 
penetrating injury, these pathogens have been increasingly 
recognized to cause sinusitis, pneumonia, and disseminated 
infection in immunocompromised patients. Laboratory and 
clinical studies also demonstrate that these organisms have a 
high propensity for infection of the central nervous system. 
Bipolaris species 
Bipolaris spp. are the most common cause of phaeomycotic 
sinusitis [105-1071. Trahtionally, Bipolaris sinusitis has been 
particularly refractory to amphotericin B. Recent findings, 
however, indicate that itraconazole is active against Bipolaris 
sinusitis, including cases which have been refractory to 
amphotericin B [108]. The same case series also indicates that 
itraconazole can be beneficial in treatment of refractory 
phaeohyphomycosis caused by other dematiaceous moulds, 
suggesting an important role of itraconazole and, perhaps, the 
novel triazoles [44,109] in the initial management’of these 
infections (Table 2). Bipolaris also may cause pneumonia, 
fungemia, and disseminated infection [I 1&113]. 
Cladophialophora bantiana 
Cladophialophora bantiana (previously termed Xylohypha banti- 
ana, Cladosporium bantianum, and Cladosporium trichoides) has a 
high propensity for CNS infection, which is often fatal [114- 
1171. Notably, patients with CNS infections caused by 
Cladophialophora bantiana may have no apparent immunosup- 
pression, but stiU succumb to h g h  morbidity and mortality. 
CNS infection may be best managed with surgical resection 
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Table 2 Chemotherapy of invasive infections by dematiaceous moulds 
~ _ _  
Fungal disease Management 
Bipolaris infections 
Cladophialophora infections 
Dactylaria infections 
Ahernaria infections 
Curvularia infections 
Wangiella infections 
D-AmB [1.C-1.5 mg/kg/d] 
or 
AmB lipid formulations? [5 mg/kg/d starting dose] 
or 
ltraconazolegt [200-600 mg/d] 
or 
Third-generation antifungal triazoles 1 [investigational] 
5-FC # [ lo0  mg/kg/d] 
~ ~~~~~ ~ 
#Monitoring of serum levels required (<lo0 pg/mL; target: 40-60 pg/mL). Dose adjustment with reduced creatinine cleara?ce. 
tln patients intolerant to high-dose D-AmB. 
$In stable patients with non life-threatening infections. 
over 3 days. Maximum: 600 mg/d. Intravenous therapy: 200 mg bid over 2 days, followed by 200 mg qd (maximum: 14 days). 
Monitoring of serum levels recommended (target: >0.5 fig/mL [HPLC] or >2.0 pg/mL [bio-assay] before next dose). Loading dose: 200 mg tid 
Includes posaconazole, ravuconazole, and voriconazole. 
[114]. The state of encapsulation and inflammation of the 
CNS lesion appears to be critical in determining outcome, 
independent of antifungal chemotherapy. Lesions, which were 
solitary, encapsulated, granulomatous and resectable, were 
associated with a good prognosis. Those lesions that were 
multiple, poorly encapsulated, nongranulomatous and multi- 
focal had a poor prognosis [114]. In the absence of a 
therapeutic standard, the practical approach to therapy is a 
combination of surgery with systemic antifungal chemother- 
apy consisting of high-dose amphotericin B. Broad-spectrum 
antifhngal triazoles such as itraconazole or voriconazole have 
consistent and potent antifungal activity in vitro [72,109] that 
appears to be fungicidal [46] and may provide alternative 
therapies (Table 2). 
Other dematiaceous moulds 
Other dematiaceous fungal pathogens are worthy of note. 
Ramichloridium obovoideum ( R .  mackenziei) is a well-known 
cause ofsinusitis and CNS infection in the Middle East [118,119]. 
This organism should be considered as an etiological agent in 
patients referred from this regon of the world and who 
manifest signs of sinusitis or CNS infection. Recent experi- 
mental studies indicate that thrd-generation triazoles may 
represent an advantage in chemotherapy of these infections 
[72,120]. Although uncommon, Dactylaria gaffopava (Ochroconis 
gallopava) causes an aggressive CNS infection in immuno- 
compromised patients (121,1223. Apart &om amphotericin B, 
the organism may be susceptible to itraconazole and 
voriconazole [109]. Its recovery tiom any clinical specimen 
in an immunocompromised host should prompt a careful 
neurological exam, including diagnostic imaging. Another 
pathogen, Wangiella (Exophiala) dermatitidis, is recovered in 
cultures of clinical specimens as a dematiaceous yeast; 
however, this organism is dimorphic and develops hyphae in 
human tissue. W. dermatitidis can cause catheter-related 
fungemia [123-1251, has a high propensity for CNS infection 
and is frequently clinically resistant to conventional antifungal 
agents [103,124]. Recent in vitro studies in a few strains, 
however, show potent and cidal activity of amphotericin B, 
itraconazole and voriconazole [46] (Table 2). 
Zygomycetes 
Zygomycetes constitute a class of organisms that are 
characterized by the presence of sparsely septated, broad and 
polymorphc hyphae in tissue. They are dwided into two 
orders, i.e. the Mucorales and Entomophthorales [126,127]. 
The Entomophthorales (Conidiobolus and Basidiobolus spp. 
respectively) are true pathogens, causing infections of the nasal 
submucosa (rhinoenthomophthoromycosis) and subcutaneous 
infections of extremities and trunk (lobomycosis) predomi- 
nantly in tropical regions [127,128]. While these organisms are 
not angioinvasive and rarely disseminate in nonimmunocom- 
promised individuals, occasional cases of disseminated and 
angioinvasive msease have been described in immunocom- 
promised patients [129], suggesting a possible emerging role 
for these organisms as opportunists [127]. 
The majority of cases of zygomycosis (also referred to in the 
literature as mucormycosis or phycomycosis) are caused by the 
Mucorales [126,128]. The Mucorales are notorious for causing 
devastating deeply invasive infections in immunocompro- 
mised patients [126,128,130]. While Rhizopus spp. is the most 
commonly implicated organism [126], an expanding spectrum 
of other Zygomycetes has been reported during the past 
decade, including but not limited to Mucor, Rhizomucor, 
Absidia, Apophysomyces, Cunninghamella, and Cokeromyces 
[126,130-1381. Cunninghamella bertholletiae is associated with 
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locahzed or msseminated infection in immunocompromised 
patients or those receiving desfenioxamine therapy [131- 
133,1361 and may be the cause of breakthrough fungal 
infections in neutropenic patients receiving itraconazole 
prophylaxis [138]. In contrast to R. oyzue,  seldom does C. 
bertholletiue cause rhinocerebral zygomycosis in patients with 
diabetic ketoacidosis. 
In immunocompromised or debilitated hosts, the Zygomy- 
cetes have a high propensity for invading blood vessels, for 
evoking a rapidly deteriorating clinical course refractory to 
antifungal therapy, and for causing high mortality [126,128]. 
Zygomycosis may develop in neutropenic states, with 
corticosteroid therapy, after solid organ and bone marrow 
transplantation, in patients with uncontrolled diabetic ketoa- 
cidosis or with bums, following desferrioxamine therapy for 
management of iron and aluminum overload states [139], in 
very-low birth weight infants [137], and in patients with 
advanced HIV-infection [9]. 
Infection may develop at various tissue sites and may be 
classified as follows: (1) rhinocerebral; (2) pulmonary; (3) 
cutaneous; (4) abdominal-pelvic and gastric; (5) miscellaneous 
sites; and (6) disseminated disease. Rhinocerebral, pulmonary 
and disseminated zygomycosis are the most frequently 
encountered conditions and, at the same time, among the 
most llminant fungal infections [126,128]. Rhinocerebral 
zygomycosis usually begins as an infection of the maxillary or 
ethmoid sinuses, whch progresses to invade the orbit, 
cavernous sinus and the brain. Hemorrhagic necrosis by blood 
vessel invasion and thrombosis is typical. A black eschar on the 
palatine or nasal mucosa and drainage of a black discharge from 
the eye are characteristic manifestations of tissue infarction 
[126]. However, these features may also be observed in 
infections by other filamentous fungi, and are not necessarily 
pathognomonic for the Zygomycetes [128]. Further clinical 
symptoms of rhinocerebral zygomycosis may include unilateral 
headache, ocular irritation, periorbital swelling or numbness, 
blurred vision, nasal congestion, or epistaxis. The onset of new 
ocular complaints in a diabetic patient, a patient receiving 
desferrioxamine, or a pharmacologically immunosuppressed 
patient should prompt a careful investigation for early 
rhinocerebral zygomycosis. Rhinocerebral zygomycosis may 
either progress rapidly, resulting in death within a few days, or 
it may be a slowly progressive, but relentless process [128]. A 
detailed radiographic evaluation, includmg computerized 
tomographic (CT) scans or magnetic resonance imaging 
(MRI) is needed to assess the anatomic extent of suspected 
rhinocerebral zygomycosis and to guide surgcal resection of 
infected tissue. 
The presentation of p u l m o ~ r y  zygomycosis in granulocy- 
topenic patients resembles pulmonary aspergdlosis with 
persistent fever and pulmonary infiltrates r e k t o r y  to 
antibacterial chemotherapy [130]. The clinical manifestations 
of pulmonary zygomycosis are a reflection of its pathophysiol- 
ogy: initial bronchopneumonia is followed by pulmonary 
vascular invasion, thrombosis and hemorrhagic infarction, 
with potential dissemination to extrapulmonary sites or 
massive hemorrhage. The sensitivity of cultures from 
respiratory specimens is low: in a recent series, a culture 
positive for zygomycetes was typically a p r e t e h n a l  finding in 
btal cases [130]. 
The mainstay of treatment of invasive zygomycosis consists 
of aggressive surgery for amenable lesions and high-dose 
amphotericin B (1.0-1.5 mg/kg/day of D-AmB) (Table 3). 
Triazoles or the echinocandins are inactive as single agents 
[39,42,46,60,74,140]. Because there are currently no alter- 
natives to amphotericin B, an accurate histological or 
microbiological diagnosis is essential. Critical to success& 
outcome of zygomycoses is the reversal of the immunological 
or metabolic defects that precipitated its development [128]. 
These strategies include reversal of granulocytopenia, if 
present, discontinuation of corticosteroids, and correction of 
metabolic acidosis. The lipid formulations of amphotericin B 
may reduce the nephrotoxicity of aggressive amphotericin B 
therapy [141-1431; patients who are neutropenic may benefit 
from colony stimulating fictors to accelerate neutrophil 
recovery [141]. 
EMERGING DIMORPHIC MOULDS 
Patients with impaired cellular immunity as a result of 
allogeneic marrow or solid organ transplantation, corticoster- 
oid therapy or HIV infection, who reside or return from 
endemic areas, are at increased risk for pulmonary and 
msseminated infections caused by Coaidioides immitis, Histo- 
plasma cupsulatum, and perhaps, other endemic moulds [13]. By 
comparison, Penidlium murne8ei is a newly recognized 
dlmorphic mould that has emerged as a frequent complication 
in individuals with advanced HIV disease in South-east Asia 
and China, and has been reported from Europe, A u s d a  and 
the USA in HIV-infected travellen returning from these areas 
Table 3 Chemotherapy of invasive infections by zygomycetes 
D-AmB [I 0-1 5 mg/kg/d] 
Am6 lipid formulatron [ $ 5  mg/kg/d 
Mucorales infections 
Rhrzopus spp or 
Mucor spp 
Absrdra spp starting dose] 
Rhrzornucor spp 
Apophysornyces spp 
Cunnrgharnella spp 
Cokerornyces spp 
Conidrobolus spp 
Basidiobolus spp 
Entomophthorales infections 
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[ 144,1451. 
W e  other Penidlium spp. are hyallne saprophytic moulds 
that often contaminate plates in the clinical microbiology 
laboratory but rarely cause infection [2,146,147], P. mameffei is 
the only dimorphic Penicillium species. It is filamentous at 
room temperature and has a characteristic red diffusible 
pigment on prolonged incubation. Existing in the filamentous 
stage at ambient temperature, the conidia from this form in the 
environment likely enter through the respiratory tract [ I l l  and 
undergo conversion to an elongated yeast form in tissues and 
body fluids [148]. P. mameffei is a predominantly intracellular 
pathogen; it divides by binary fission, not by budding in vivo. 
Pulmonary alveolar macrophages and peripheral blood 
monocytes may be replete with multiple yeast forms with 
the characteristic binary septate morphology. Cell-mediated 
immunity appears to play the central role in host defense [149], 
but cytokine-activated polymorphonuclear leukocytes may 
contribute additional antifungal activity [150]. Thus, impaired 
regulation of pulmonary phagocytic functions may be 
explanatory for the high disease rates in environmentally 
exposed individuals with advanced HIV infection [ll].  
The bamboo rat is imputed in the epidemiology of 
penicilliosis. The bamboo rat, which is not a rat but a 
member of the genus Rhitomus (Rhizomus pmnosis), has been 
found to harbor and sometimes succumb to P. marnefei. While 
similar genotypes of P. marnefei have been identified in 
bamboo rats and infected humans [151], this relationship may 
be coincidental. Indeed, a case control study demonstrated that 
patients with a recent history of occupational and other 
exposure to soil, especially during the rainy season, were more 
likely to present with P. mameffei infection. In contrast, history 
of exposure to or consumption of bamboo rats, the only 
known nonhuman host of P. mamejiei, was not a risk factor for 
infection, suggesting an environmental reservoir of the 
organism in soil [152]. 
The most common presenting features of AIDS-associated 
P. mameffei infection in both children and adults include fever, 
generalized lymphadenopathy, hepatosplenomegaly, pulmon- 
ary infiltrate, weight loss or failure to thrive, marked anemia 
and a generaked papular skin rash reminiscent of mollusca 
contagiosa [144,145]. In general, the diagnosis is not hfficult if 
the clinical picture is recognized, and it can be readily 
established by isolation of the organism on conventional media 
from blood and skin lesions, or, more invasively, from bone 
marrow aspirates or lymph-node biopsies. A presumptive 
diagnosis can be made by microscopic examination of 
appropriately stained smears from skin lesions, bone marrow 
aspirates, or biopsy material [144,145]. In vitro studies show 
that ketoconazole and itraconazole are the most active agents 
[153,154]; however, amphotericin B at dosages of 0.5-1.0 
mg/kg demonstrated the best response rates for induction 
therapy in the clinical setting [154,155] (Table 4). Recurrence 
is common in HIV infection, and life-long maintenance wxth 
either itraconazole or ketoconazole [145,156] is indicated and 
effective in reducing the risk of recurrence [156]. 
EMERGING YEAST PATHOGENS 
Trichosporon species 
Trichosporon spp. are pathogenic yeasts that cause life threaten- 
ing disseminated infection in immunocompromised patients 
[157-1601. Historically, the mortality associated with dis- 
seminated trichosporonosis has been between 60% and 80% 
[157,159,161], but prognosis has considerably improved as a 
result of advances in our knowledge regarding diagnosis, 
treatment and prevention. As characterized by hyphae, 
pseudohyphae, blastoconidia and arthroconidia, Trichosporon 
species are composed of morphologically, biochemically and 
genetically distinct subgroups of organisms; these differences 
become apparent when isolates from deep, superficial and 
environmental isolates are compared [162,163]. As a conse- 
quence, the genus Trichosporon has undergone considerable 
Table 4 Chemotherapy of invasive infections by dimorphic moulds 
Fungal disease Management  
Histoplasmosis D-AmB [0.5-1 .O mg/kg/d]' 
Itraconazol@$ [200-400 mg/d] 
L-AmB [AmBisomeTM; 5 mg/kg/d; 
investigational] t 
Blastomycosis and 
Paracoccidioidomycosis Itraconazole$$ [200-400 mg/d] 
Penicilliosis (P. rnarneffeb 
D-AmB tO.5-1 .O rngikgid]" 
D-Am6 [0.5-1.0 mg/kg/d]' 
Itraconazol@$ [200-400 mg/d] 
Coccidioidomycosis D-AmB [0.5-1 .O mg/kg/d]" 
Fluconazolep [20[400-800 mg/d] 
D-AmB [0.5-1 .O mg/kg/d]' 
Terbinafine [250 mg/d; 
Sporotrichosis 
investigational]q 
'May be replaced by lipid formulations of AmB in patients who are 
intolerant to D-AmB, although dosages and antifungal efficacy have 
not been formally established. 
§In stable patients with mild-to-moderate, non-CNS disease, or for 
long-term maintenance. 
$Monitoring of serum levels recommended (>0 .5  pg/mL [HPLC] or 
22.0  pg/mL [bio-assay] before next dose). Loading dose: 200 mg tid 
over 3 days. Maximum: 600 mg/d. Intravenous therapy: 200 mg bid 
over 2 days, followed by 200 mg qd (maximum: 14 days). 
t l n  patients intolerant or refractory to D-AmB. 
PLoading dose: Twice the target dose on the first day of treatment. 
Dose adjustment may be required with reduced creatinine clearance 
and high dosages. 
TCutaneous forms only. 
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revision in recent years. A proposal has been made for 
Trichosporon beigelii to be revised to five species, includmg 
Trichosporon asahii, the most common cause of fatal dissemi- 
nated infection [164]. However, these revisions remain 
controversial, and although the genus Trichosporon includes 
more than one species, the term Trichosporon will be used here 
for simplicity. 
Trichosporon is a common cause of white piedra, which is a 
simple infection at the kstal end of hairshafis. It also has been 
well characterized as the cause of summer type hypersensitivity 
in Japan. In immunocompromised patients, particularly those 
with neutropenia and mucosal ksruption caused by cytotoxic 
chemotherapy, Trichosporon causes devastating infection. The 
portals of entry are the gastrointestinal tract and vascular 
catheters; however, aspiration may also occur, leading to 
bronchopneumonia. From these entry sites, the organism can 
disseminate widely, resulting in a characteristic constellation of 
findings that include fungemia, renal failure, pulmonary 
infiltrates, multiple cutaneous lesions and characteristic 
chorioretinitis; in patients who recover &om neutropenia, this 
process can evolve into a chronic hepatic trichosporonosis 
[ 1651. Not uncommonly, acute trichosporonosis presents with 
a cascade of rapidly evolving skin lesions in a neutropenic 
patient who is receiving empirical amphotericin B for 
refractory fever. Laboratory investigations of these organisms 
have demonstrated that they may be inhibited but not killed 
by safely achievable levels of amphotericin B [166]. 
Because the organism belongs to hemibasidiomycetes and, 
hence, is related to C. neojiomans, it expresses an antigen that 
cross-reacts with glucuronoxylomannan (GXM) [167-1691. 
The GXM-like antigen is expressed in significantly higher 
concentrations in isolates from patients with fungemia in 
comparison to environmental sites, and importantly, phago- 
cytosis and microbicidal activity against Trichosporon are 
profoundly suppressed in comparison to those of C. albicans 
[169]. The GXM-like antigen has been shown to be capable of 
suppressing phagocytosis particularly by the monocyte popu- 
lation, conceivably contributing to the phenomenon of 
persistent fungemia despite amphotericin B therapy. Of note, 
in vitro treatment of monocytes with GMCSF, MCSF or 
interferon gamma is able to reverse this immunosuppression 
and enhance phagocytosis and microbicidal activity of 
monocytes against Trichosporon 11701. 
A persistently neutropenic rabbit model of gastrointestinal 
and disseminated trichosporonosis, which simulates the 
previously mentioned clinical manifestations of this infection, 
was developed to investigate the pathogenesis and treatment of 
this refractory infection [171]. Treatment with amphotericin B 
deoxycholate (1 mg/kg per day) and the multdamellar lipid 
formulation [172] of amphotericin B (5 mg/kg per day) were 
unable to clear tissues in .comparison with saline-treated 
controls. This lack of amphotericin B efficacy was consistent 
with the clinical experience in profoundly neutropenic 
patients [157,161]. In contrast, antifungal triazoles, such as 
fluconazole and SCH-39304, resulted in a significant decline 
in tissue burden [171]. These findings are supported by the 
results obtained in a murine model of disseminated trichos- 
poronosis, that additionally suggested enhanced antifungal 
activity in vivo of the combination of fluconazole with 
amphotericin B [161]. Thus, the current data support 
treatment of disseminated trichosporonosis in persistently 
neutropenic patients with fluconazole and preferentially 
GMCSF and possibly, the combination of fluconazole and 
amphotericin B. Non-neutropenic patients may be treated 
with fluconazole alone [161,173]. Third-generation triazoles 
also are active against Trichosporon [39,44], whereas the current 
echinocandins appear inactive [44,140] (Table 5) .  
Blastoschizomyces capitatus 
Blastoschizomyces capitatus (formerly: Trichorporon capitatum), 
although superficially similar to T. beigelii, is characterized by 
the predominant formation of anelloconidia instead of 
arthroconidia. In neutropenic patients, B. capitatus produces 
a pattern of infection similar to that of Trichospovon, but with 
more frequent CNS involvement. Blood cultures are usually 
positive during acute disseminated infections. A chronic 
disseminated form similar to chronic disseminated candidiasis 
can result in patients who recover from neutropenia [174- 
1771. The optimal approach to therapy remains to be defined. 
Similar to Trichosporon, B. capitatus appears to have decreased 
susceptibility to amphotericin B [175,178,1174]. Fluconazole 
and flucytosine appear to be more active in vitro [177], but 
fluconazole-resistant strains have been reported as nosocomial 
pathogens [179]. Similar to Trichosporon, therapy with 
fluconazole plus amphotericin B and adjuvant immunotherapy 
[180] may be the most rational strategy at the present time 
(Table 5). 
Malassezia species 
Malassezia fuffur and Malassezia pachydematidis are lipophilic 
yeasts that cause tinea versicolor, infectious folliculitis, and 
catheter-associated fungemia [181-1841. Fungema caused by 
M. fuffur typically develops in the setting of parented 
administration of lipids via central venous catheters 
[185,186], and M. pachydematidis has been reported as 
nosocomial infection transmitted from dogs via the hands of 
health-care workers to preterm neonates [187]. Infection 
caused by Malassezia spp. may present as persistent fever, 
fungemia, pulmonary infiltrates, and thrombocytopenia. 
However, the organism seldom disseminates to cause disease 
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Table 5 Chemotherapy of invasive infections emerging yeast pathogens 
Fungal disease Management 
Trichosporon infections 
Blastoschizom yces infections Second line: 
Fluconazolep [400-800 mg/dl + D-AmB [ > 1 .O mg/kg/d]' 
Third generation antifungal triazolesq [investigational] 
D-AmB [0.5-1 .O mg/kg/d] or 
AmB lipid formulationst [5 mg/kg/d starting dose] or 
FluconazolepP [400-800 mg/d] 
D-AmB E0.5-1 .O mglkgid] i 5-FC #[lo0 mg/kg/d] or 
AmB lipid formulationst [5 mg/kg/d starting dose] 
FluconazoleP$ [400-800 mg/d] or 
Third generation antifungal triazolesq [investigational] 
Malassezia infections 
Other rare yeast infections 
Rhodotorula rubra Second line: 
Saccharomyces cerevisiae 
Hansenula anomala 
C. laurentii, and others 
PLoading dose: Twice the target dose on the first day of treatment. Dose adjustment may be required with reduced creatinine clearance and high 
dosages. 
'In combination with fluconazole in neutropenic patients. 
vlncludes posaconazole, ravuconazole, and voriconazole 
t l n  patients intolerant to D-AmB. 
$Only for identified and in virro susceptible isolates 
#Monitoring of serum levels required ( <lo0 pg/mL; target: 4060  pg/mL). Dose adjustment with reduced creatinine clearance. 
in other sites [181-1841. It should be noted that isolated 
folliculitis in neutropenic patients may simulate the lesions of 
acute disseminated candidiasis [188]. A direct smear of these 
lesions, however, will demonstrate characteristic organisms of 
M. fur+. 
Laboratory diagnosis is &cilitated by the addition of a lipid 
source such as olive oil [182]. Management includes the 
discontinuation of parenteral lipids, removal of the vascular 
catheter, if feasible, and administration of an antifungal azole 
or amphotericin B [10,13,183,184,189] (Table 5), although 
Malassezia spp. may not be sufficiently susceptible to 
amphotericin B. 
Other emerging yeast pathogens 
Invasive infections by other unusual yeast pathogens are more 
and more frequently encountered in profoundly immuno- 
compromised patients. They may present with a broad range 
of clinical manifestations and include, among others, Sacchar- 
omyces cerevisiae, Rhodotorula rubra, Hansenula anomala, and 
Cryptococcus taurentii [176,19@-194]. Of note, a recent report 
&om a single cancer center suggests that invasive non-Candida 
yeast infections collectively carry a significantly worse 
prognosis than invasive Candida albicans infections [176]. 
In immunocompromised patients, these biologically distinct 
pathogens can cause fungemia and deeply invasive localized or 
disseminated infections [2,9,194-1971. The approach to 
successful management is necessarily individual, but includes 
antifungal chemotherapy and, intuitively, the removal of 
potentially colonized intravascular catheters. Most clinical 
Table 6 Adjunctive immunoreconstitution in infections by emerging 
pathogens 
Dose-reduction or discontinuation of glucocorticosteroids 
Neutropenic patients: 
G-or GM-CSF 
G-CSF elicited granulocytes [investigational] 
GM-CSF or y-IFN [investigational] 
Non-neutropenic patients: 
isolates of the four pathogens discussed in this subsection 
are susceptible to amphotericin B and flucytosine in oitro, 
whereas fluconazole and other triazoles have variable activity 
[39,193,197-2001. Therefore, high-dose amphotericin B, 
potentially in combination with flucytosine, appears to be 
the current first line of antifungal chemotherapy (Table 5). 
FUTURE DIRECTIONS IN ANTIFUNGAL THERAPY 
Infections by previously uncommon fungal opportunists are 
evolving against a background of a much greater magnitude of 
invasive candidiasis, especially nonalbicans Candida spp., and 
of invasive pulmonary aspergdlosis. In response to this 
expanding challenge, novel therapeutic and preventive 
strateges are desperately needed. 
For almost four decades, amphotericin B deoxycholate has 
been the cornerstone of chemotherapy for most invasive 
fungal infections. The major advantage of this agent is its broad 
antifungal spectrum and its concentration-dependent fungici- 
dal action against most susceptible fungi [97]. The lipid 
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Table 7 Adjunctive interventional management of infections by emerging pathogens 
Fungal infection and site 
Hyaline and dematiaceous moulds 
Suggested intervention" 
Pulmonary infections Potential indications for surgery: 
Pulmonary hemorrhage from an amenable lesion 
Impeding arosion of a major pulmonary artery 
Invasion of pericardium or thoracic wall 
Disease progression despite neutrophil recovery 
Further intensive chemotherapy or stem cell 
transplantation 
Continuing profound immunosuppression 
Minimally invasive surgery for culture, biopsy and 
Debridement for progressive invasive disease 
Excision, if feasible, or debridement and drainage 
Removal of indwelling central venous catheters 
Individualized approach 
Paranasal sinus 
infections aeration 
Primary skin/soft tissue 
Fungemia 
Infections of all other sites 
infections 
Opportunistic yeasts 
Fungemia 
Focal lesions 
Meningoencephalitis and 
increased intracranial pressure ineffective 
Removal of indwelling central venous catheters 
Removal Df potentially infected plastic material 
Debridement/drainage 
Shunt-placement, if medical therapy is 
'All invasive surgical interventions require a multidisciplinary approach, involving internist, surgeon, radiologist and microbiologist, and often, expert 
consultation. 
formulations of amphotericin B (amphotericin B colloidal 
dispersion, Amphocil or Amphotec; amphotericin B lipid 
complex, Abelcet; and the small unilamellar liposomal 
formulation of amphotericin B, AmBisome) have been shown 
to be as active as conventional amphotericin B but less 
nephrotoxic in the treatment of invasive infections by classic 
fungal opportunists [201,202]. They allow for a safer 
administration of high h l y  dosages of amphotericin B and 
have an important role in the treatment of emerging fungal 
pathogens that need comparatively higher amphotericin B 
concentrations for growth inhibition and killing. 
Apart &om the ongoing search for new compounds and 
novel targets [203], the thrd-generation antifungal triazoles 
(ravuconazole, posaconazole and voriconazole) have increased 
inhibitory potency against some of the emerging hyaline 
moulds and, similar to itraconazole, cidal activity against 
certain dematiaceous moulds [204]. The novel class of 
echinocandins targets the ceU wall of classic fungal opporm- 
nists, as well as Pneumocystis cannii, by noncompetitive 
inhibition of 1,3-beta-glucan synthesis [205]. The potential 
usefulness of the echinocandins as single therapeutics against 
the emerging fungal opportunists, however, remains to be 
elucidated. 
Because reversal of deficiencies in host defenses is a 
prerequisite for successful outcome of a l l  opportunistic 
infections, augmentation of host response in treatment or 
prevention of invasive fungal infections is being developed 
through several avenues: direct administcltion of recombinant 
cytokines; GCSF-stimulated granulocyte transfusions; hames- 
sing of antimicrobial peptides for protection of mucosal or 
systemic antifungal therapy; adoptive immunotherapy; and 
vaccine development, particularly for C. neofomans and the 
dimorphic moulds [206]. 
CONCLUSIONS 
The fungal pathogens that have emerged during the past 
decade have developed in an expanding population of 
immunocompromised hosts, new antifungal selective pres- 
sures, and shifting environmental conditions. In light of past 
and present epidemiological trends, invasive fungal infections 
will probably remam a gequent and important complication 
in immunocompromised patients. An expanded and refined 
drug arsenal, elucidation of pathogenesis and resistance 
mechanisms, establishment of in. vitrdin vivo correlation, 
incorporation of pharmacodynamics, combination- and im- 
munotherapies offer hope for further substantial progress in 
prevention and treatment of previously uncommon opporm- 
nistic mycoses. 
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